Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study

被引:4
|
作者
Ullah, Asad [1 ]
Saeed, Omer [2 ]
Karki, Nabin Raj [3 ]
Goodbee, Mya [4 ]
Yasinzai, Abdul Qahar Khan [5 ]
Waheed, Abdul [6 ]
Heneidi, Saleh [7 ]
Thomas, Anish [8 ]
Karim, Nagla Abdel [9 ]
Johnson, Joyce [1 ]
Del Rivero, Jaydira [8 ]
Khan, Jaffar [2 ]
机构
[1] Vanderbilt Univ Sch Med, Dept Pathol, Nashville, TN 37232 USA
[2] Indiana Univ, Indiana Sch Med, Dept Pathol, Indianapolis, IN 46202 USA
[3] Univ S Alabama, Dept Hematol & Oncol, Mobile, AL 36688 USA
[4] Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA
[5] Bolan Med Coll, Dept Med, Quetta 83700, Pakistan
[6] San Joaquin Gen Hosp, Dept Surg, San Joaquin, CA 95231 USA
[7] Cedars Sinai Med Ctr, Dept Mol Pathol, Los Angeles, CA 90048 USA
[8] Natl Inst Hlth NIH, Dept Hematol & Oncol, Bethesda, MD 20814 USA
[9] Inova Schar Canc Inst, Dept Hematol & Oncol, Fairfax, VA 22031 USA
关键词
combined small cell; lung cancer; histology; chemotherapy; molecular changes; CANCER; SCLC;
D O I
10.3390/jcm12030991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Primary lung cancer is the most common cause of cancer-related mortality in the United States (US). Approximately 90% of lung cancers are associated with smoking and the use of other tobacco products. Based on histology, lung cancers are divided into small-cell lung carcinomas (SCLCs) and non-small-cell lung carcinomas (NSCLCs). Most SCLCs are of the pure subtype, while the rare combined SCLCs contain elements of both small-cell and non-small-cell morphologies. This study sought to evaluate the demographics, clinical factors, molecular abnormalities, treatment approaches, and survival outcomes with combined SCLC and NSCLCs. Materials and Methods: Data on 2126 combined SCLC patients was extracted from the Surveillance Epidemiology and End Result (SEER) database from 2000 to 2018. Data extracted for analyses included age, sex, race, tumor size, tumor location, metastasis status, stage at diagnosis, treatment received, and treatment outcomes. Multivariate analysis was performed using Statistical Product and Service Solutions (SPSS) software. Results: The patients had a median age of 68 years; 43.9% of the patients were female and 56.1% were male; 84.5% were White and 11.7% were African Americans. The majority of patients had a poorly differentiated disease at 29.6%; 17% were undifferentiated, 3.2% were moderately differentiated, and 0.8% were well differentiated. Chemotherapy was the most common treatment modality (45.3%); 17% underwent surgery only, 10.3% underwent surgery followed by adjuvant chemotherapy, and 10% underwent radiation after surgery. Five-year cancer-specific survival was 15.2% with surgery alone, and combined surgery and chemotherapy provided the highest percentages (38.3% and 34.7%, respectively). Females had significantly higher 1- and 5-year cancer-specific survival rates compared to males (59.3% and 29.9% vs. 48.0% and 23.7, respectively; p < 0.001). Well-differentiated tumors had significantly higher survival compared to other gradings (p < 0.001). Survival decreased as tumor staging moved distally from localized to regional to distant (p < 0.001). Metastasis to bone, liver, brain, and lung significantly decreased survival in comparison to patients who did not have any metastasis (p < 0.001). Females had significantly shorter survival compared to their counterparts when metastasis was to the bone, brain, or liver (p < 0.001). Multivariate analysis identified male sex (Hazard Ratio (HR) = 1.2), undifferentiated grade (HR = 1.9), regional extent of disease (HR = 1.7), distant extent of disease (HR = 3.7), and metastasis to liver (HR = 3.5) as variables associated with worse survival. Conclusion: Combined SCLC is overall very rare. However, the frequency of presentation with combined SCLC is on the rise, in part due to improvements in diagnostic techniques. Despite advances in therapies, treating combined SCLC is challenging, and novel therapies are not utilized, owing to low rates of targetable mutations. Combined SCLC has higher survival rates if well differentiated.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Timing of treatment in small-cell lung cancer
    Bhandari, Shruti
    Danh Pham
    Pinkston, Christina
    Oechsli, Malgorzata
    Kloecker, Goetz
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [22] SMALL-CELL LUNG-CANCER TREATMENT
    LEBEAU, B
    SCHULLER, MP
    REVUE DE MEDECINE INTERNE, 1994, 15 (06): : 423 - 427
  • [23] The prognosis analysis of organ metastatic patterns in lung large cell neuroendocrine carcinoma: A population-based study
    Chen, Kai
    Dai, Peiling
    Ni, Jiangwei
    Xiang, Yili
    Gu, Lizhong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer
    Batra, Atul
    Yusuf, Dimas
    Hurry, Manjusha
    Walton, Ryan N.
    Devost, Natalie
    Farrer, Christie
    Cheung, Winson Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : 512 - 518
  • [25] Comparative study of large cell neuroendocrine carcinoma and small cell lung carcinoma in high-grade neuroendocrine tumors of the lung: a large population-based study
    Wang, Jian
    Ye, Ling
    Cai, Hui
    Jin, Meiling
    JOURNAL OF CANCER, 2019, 10 (18): : 4226 - 4236
  • [26] Advances in the Treatment of Small-Cell Lung Cancer
    Kalemkerian, Gregory P.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 32 (01) : 94 - 101
  • [27] Topotecan for the treatment of small-cell lung cancer
    Nicum, Shibani J.
    O'Brien, Mary E. R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (06) : 795 - 801
  • [28] Results of surgical resection in the treatment of small-cell lung cancer
    Yazici, Ulku
    Aydin, Ertan
    Tastepe, Irfan
    Gulhan, Erkmen
    Yaran, Pinar
    Karaoglanoglu, Nurettin
    Agackiran, Yetkin
    Kaya, Sadi
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2011, 19 (04): : 598 - 602
  • [29] SURGICAL-TREATMENT OF SMALL-CELL CARCINOMA OF THE LUNG - ADVANTAGE OF PREOPERATIVE CHEMOTHERAPY
    WADA, H
    YOKOMISE, H
    TANAKA, F
    HIRATA, T
    FUKUSE, T
    BANDO, T
    INUI, K
    IKE, O
    MIZUNO, H
    HITOMI, S
    LUNG CANCER, 1995, 13 (01) : 45 - 56
  • [30] A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma
    Isaka, Mitsuhiro
    Nakagawa, Kazuo
    Ohde, Yasuhisa
    Okumura, Takehiro
    Watanabe, Reiko
    Ito, Ichiro
    Nakajima, Takashi
    Kondo, Haruhiko
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2012, 41 (04) : 841 - 846